Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States.
The last earnings update was 141 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Avalon GloboCare. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Avalon GloboCare's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avalon GloboCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Avalon GloboCare's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Avalon GloboCare's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Avalon GloboCare's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Avalon GloboCare is high growth as no earnings estimate data is available.
Unable to determine if Avalon GloboCare is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Avalon GloboCare's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Avalon GloboCare's finances.
The net worth of a company is the difference between its assets and liabilities.
Avalon GloboCare's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Avalon GloboCare's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Avalon GloboCare's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 3.1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. David K. Jin, M.D., Ph.D., serves as the Chief Executive Officer and President of Avalon Globocare Corp. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medical Institute and Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. He served as the Chief Executive Officer of Global Technologies Corp. since September 14, 2016 and also served as its President since October 10, 2016. He served as the Chief Medical Officer of BioTime, Inc. from 2009 to 2016. He served as the Chief Medical Officer at OncoCyte Corporation. He also worked for the Food and Drug Administration in the United States as Medical Reviewer at the Oncology Product Development Division as well as Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology and stem cell-based technology development. He serves as a Director at Avalon Globocare Corp. He served as a Director of Global Technologies Corp. since September 14, 2016. He is Principle Investigator in more than 15 pre-clinical and clinical trials, as well as an Author/Co-Author of over 80 peer-reviewed scientific abstracts, articles, reviews and book chapters. He received his clinical training and subsequent faculty tenure at the NewYork-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology and clinical oncology. He was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015. Dr. Jin studied Medicine at SUNY Downstate College of Medicine in Brooklyn, NY.
David's compensation has increased whilst company is loss making.
David's remuneration is lower than average for companies of similar size in United States of America.
CEO, President & Director
Chief Financial Officer
COO & Secretary
Co-CEO & Director of GenExsome
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Avalon GloboCare board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
CEO, President & Director
Co-CEO & Director of GenExsome
Head of Scientific & Clinical Advisory Board
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Avalon GloboCare Corp (NASDAQ:AVCO): Time For A Financial Health Check
While small-cap stocks, such as Avalon GloboCare Corp (NASDAQ:AVCO) with its market cap of US$190m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.
Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership with Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy; a research and licensing agreement with Massachusetts Institute of Technology to develop technology for cellular therapy; and strategic partnership with GE Healthcare to enhance standardized automation and bio-production for cellular medicines. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.